share_log

0.4% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Shareholders Over That Period

0.4% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Shareholders Over That Period

3年內0.4%的收益增長尚未轉化爲浙江沃沃生物製藥(深圳證券交易所代碼:300357)股東在此期間的收益
Simply Wall St ·  01/26 20:15

Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in a while. So consider, for a moment, the misfortune of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) investors who have held the stock for three years as it declined a whopping 75%. That would certainly shake our confidence in the decision to own the stock. And the ride hasn't got any smoother in recent times over the last year, with the price 58% lower in that time. Furthermore, it's down 17% in about a quarter. That's not much fun for holders. Of course, this share price action may well have been influenced by the 7.2% decline in the broader market, throughout the period.

地球上的每個投資者有時都會打壞電話。但是,如果你不止一次地面臨巨額損失,你就會遇到問題。因此,暫時考慮一下浙江沃爾沃生物製藥有限公司(深圳證券交易所代碼:300357)投資者的不幸經歷,他們持有該股三年,股價下跌了75%。這肯定會動搖我們對擁有該股決定的信心。而且在過去的一年裏,行程並沒有變得更加順利,同期價格下降了58%。此外,它在大約一個季度內下降了17%。對於持有者來說,這沒什麼好玩的。當然,這種股價走勢很可能受到了整個時期大盤下跌7.2%的影響。

With the stock having lost 5.6% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.

由於該股在過去一週下跌了5.6%,值得一看業務表現,看看是否有任何危險信號。

Check out our latest analysis for Zhejiang Wolwo Bio-Pharmaceutical

查看我們對浙江沃沃生物製藥的最新分析

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

用本傑明·格雷厄姆的話來說:從短期來看,市場是一臺投票機器,但從長遠來看,它是一臺稱重機。評估公司情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

Although the share price is down over three years, Zhejiang Wolwo Bio-Pharmaceutical actually managed to grow EPS by 1.3% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.

儘管股價在三年內下跌,但在這段時間內,浙江沃爾沃生物製藥的每股收益實際上每年增長1.3%。鑑於股價的反應,人們可能會懷疑每股收益並不能很好地指導該期間的業務表現(可能是由於一次性的虧損或收益)。或者,過去的增長預期可能不合理。

After considering the numbers, we'd posit that the the market had higher expectations of EPS growth, three years back. However, taking a look at other business metrics might shed a bit more light on the share price action.

在考慮了這些數字之後,我們認爲三年前市場對每股收益增長的預期更高。但是,查看其他業務指標可能會進一步了解股價走勢。

With a rather small yield of just 0.9% we doubt that the stock's share price is based on its dividend. Revenue is actually up 12% over the three years, so the share price drop doesn't seem to hinge on revenue, either. It's probably worth investigating Zhejiang Wolwo Bio-Pharmaceutical further; while we may be missing something on this analysis, there might also be an opportunity.

由於收益率相當低,僅爲0.9%,我們懷疑該股的股價是否基於其股息。在過去的三年中,收入實際上增長了12%,因此股價下跌似乎也不取決於收入。可能值得進一步研究浙江沃爾沃生物製藥;雖然我們在分析中可能遺漏了一些東西,但也可能有機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
SZSE:300357 Earnings and Revenue Growth January 27th 2024
SZSE: 300357 收益和收入增長 2024 年 1 月 27 日

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以在這張免費的交互式圖片中看到其資產負債表如何隨着時間的推移而增強(或減弱)。

A Different Perspective

不同的視角

While the broader market lost about 17% in the twelve months, Zhejiang Wolwo Bio-Pharmaceutical shareholders did even worse, losing 58% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 1.1%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Zhejiang Wolwo Bio-Pharmaceutical better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Zhejiang Wolwo Bio-Pharmaceutical you should know about.

儘管整個市場在十二個月中下跌了約17%,但浙江沃爾沃生物製藥的股東表現更糟,損失了58%(甚至包括股息)。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺1.1%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。長期跟蹤股價表現總是很有意思的。但是,要更好地了解浙江沃爾沃生物製藥,我們需要考慮許多其他因素。例如,考慮風險。每家公司都有它們,我們發現了一個你應該知道的浙江沃爾沃生物製藥的警告標誌。

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找中獎投資的人來說,這份最近有內幕收購的成長型公司的免費名單可能只是門票。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論